CORDIS
EU research results

CORDIS

English EN
An integrated platform enabling Theranostic applications at the Point of Primary Care

An integrated platform enabling Theranostic applications at the Point of Primary Care

Objective

TheraEDGE is an industry-driven effort to accelerate the adoption of theranostics applications in Primary Care by pushing Point of Care Test (POCT) technology far beyond its current state-of-the-art and by delivering clinical, analytical and operational breakthroughs.TheraEDGE is built around the high-incidence clinical case of early-diagnosing lower respiratory tract infections in Primary Care. Simultaneous testing for different pathogens and their antibiotic resistance will have a huge European impact:•better clinical outcomes and standards of care through more effective and timely diagnosis and treatment•improved health economics through optimization of antibiotics prescription, infection control practices and reduction of clinical visits or hospital stays•substantial business for the In Vitro Diagnostics industry through the standardisation and commercialization of innovative POCT products and systemsTheraEDGE consists of three multidisciplinary platforms:•a core Lab-On-a-Chip supporting multi-marker assays and using Single Molecule Detection (SMD) as an alternative to PCR-based molecular diagnostics. SMD removes the need for amplification and has the potential to become a key enabler for Nucleic Acid Testing at the Point of Care by providing less complex, faster, more sensitive and more specific assays•an architecture that provides Plug and Play semantic interoperability and creates opportunities for the standardisation of POCT instruments and information systems, offering radical usability, robustness and vendor interoperability improvements. Practitioners will be able to run out-of-the-box multiple compliant devices from one single PDA-based operator interface•a set of applications built on a convergent ITC platform that supports General Practitioners in their patient management and clinical decision-making, and provides therapeutic services for patient education and compliance monitoring in order to fight antibiotic misuse and abuse.

Coordinator

Biokit

Address

Can MalÉ S/N
08186 LliÇA D´Amunt

Spain

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 056 954

Administrative Contact

Francisco Javier Soler Serres (Mr)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 491 202

UNIVERSITAET BIELEFELD

Germany

EU Contribution

€ 595 344

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 458 832

INSTITUT FUER MIKROTECHNIK MAINZ GMBH

Germany

EU Contribution

€ 767 920

HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Spain

EU Contribution

€ 100 000

UNIVERSITAT DE BARCELONA

Spain

EU Contribution

€ 477 918

Systelab Technologies S.A.

Spain

EU Contribution

€ 816 433

NTE-SENER, S.A.

Spain

EU Contribution

€ 439 946

RIDGEBACK S.A.S. DI PAOLO BARATTINI & C.

Italy

EU Contribution

€ 162 961

UNIVERSITEIT TWENTE

Netherlands

EU Contribution

€ 703 800

TEKEVER TECNOLOGIAS DE INFORMACAO SA

Portugal

EU Contribution

€ 463 643

LINKOPINGS UNIVERSITET

Sweden

EU Contribution

€ 100 013

CLINICAL RESEARCH ASSOCIATES & CONSULTANTS S.R.O.

Slovakia

EU Contribution

€ 100 000

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 1 052 303

LEWIS TREVOR STANLEY MEDICAL DEVICE CONSULTANCY

United Kingdom

EU Contribution

€ 212 731

Project information

Grant agreement ID: 216027

Status

Closed project

  • Start date

    1 March 2008

  • End date

    31 August 2012

Funded under:

FP7-ICT

  • Overall budget:

    € 11 783 434

  • EU contribution

    € 8 000 000

Coordinated by:

Biokit

Spain